GSK receives US FDA file acceptance for Jemperli (dostarlimab-gxly) plus chemotherapy for the treatment of dMMR/MSI-H primary advanced or recurrent endometrial cancer
This story is reported by GSK US. Read what other outlets are saying below, then open the original report for full details.